Sermorelin Results in the Studies — Numbers, Graded
How to read this page
These are the sermorelin results that have actual numbers behind them, each tied to the study that measured it and graded by what kind of study it was. Treat any "result" without a citation as marketing until proven otherwise. The honest headline: the growth and GH/IGF-1 numbers are real and human [1][2]; the body-composition and cognition numbers people quote usually come from a related drug, tesamorelin [7]; and the regenerative and cancer "results" are from animals and computers, not people [8][9].
Nothing here is a before-and-after promise for any individual. It is a ledger of what published studies recorded, including the gaps where no durable adult outcome data exist.
Sermorelin before and after: the measured numbers
The honest sermorelin before-and-after lives in trial data, not testimonial photos. In growth-hormone-deficient children, first-year height velocity went from about 4.1 cm/year before to roughly 7-8 cm/year on once-daily GHRH(1-29) — without excessive IGF-1 [1]. In healthy older men, GH and IGF-1 rose dose-dependently over 14 days of twice-daily injections, reaching levels that no longer differed from young men, with no change in fasting glucose [2]. Pharmacokinetically, a single dose lifted GH for about three hours despite ~10-12-minute clearance [3]. Those are the genuine before/after deltas in the record. Evidence grade: human, randomized pediatric trial plus a controlled aging study.
The body-composition results belong to tesamorelin
Search "sermorelin results" and you will find dramatic fat-loss and cognition figures. The cleanest of those — a 7.4% reduction in body fat, a 117% IGF-1 increase, and a favorable cognition effect (P=0.03) — come from a randomized trial of tesamorelin at 1 mg/day for 20 weeks in 152 older adults, not from sermorelin [7]. The GHRH-axis logic is shared, but the molecule and the data are tesamorelin's. Honest reporting keeps that label attached rather than transferring the numbers. Evidence grade: human trial — of tesamorelin, a related analog.
Frontier results — real findings, wrong to call human outcomes
The regenerative-oncology results are genuine experiments with genuine numbers, just not human ones. GHRH agonist analogs increased human dermal fibroblast proliferation by more than 50% in culture and improved cell survival under stress, and topical MR-409 accelerated wound closure dose-dependently in animals [8]. A GHRH agonist improved a mouse heart-failure model [10]. The glioma "result" is an in-silico ranking across 1,018 patients that flagged recurrent glioma as most sermorelin-sensitive — a computational prediction, explicitly hypothesis-generating, not a trial outcome [9]. Evidence grade: preclinical to in-silico. Reading these as proof of human benefit is the single most common error in sermorelin write-ups, and the reason this site grades every result it lists. See sermorelin benefits for the same findings sorted by claim.